These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 27112171)

  • 21. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
    Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.
    Bedke J; Gouttefangeas C; Singh-Jasuja H; Stevanović S; Behnes CL; Stenzl A
    World J Urol; 2014 Feb; 32(1):31-8. PubMed ID: 23404195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
    Zhu Z; Liu W; Gotlieb V
    Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
    Flippot R; Escudier B; Albiges L
    Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.
    Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y
    Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of available treatment options for renal cell carcinoma.
    Derosa L; Albiges L; Massard C; Loriot Y; Fizazi K; Escudier B
    Expert Opin Drug Saf; 2016 Aug; 15(8):1097-106. PubMed ID: 27142582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
    Calvo E; Ravaud A; Bellmunt J
    Cancer Treat Rev; 2013 Jun; 39(4):366-74. PubMed ID: 22832091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Risk-adapted (immuno)therapy for renal cell carcinoma].
    Grünwald V
    Urologe A; 2018 Nov; 57(11):1326-1333. PubMed ID: 30350129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma.
    Lambea J; Anido U; Etxániz O; Flores L; Montesa Á; Sepúlveda JM; Esteban E
    Curr Oncol Rep; 2016 Nov; 18(11):66. PubMed ID: 27613167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nivolumab in the treatment of advanced renal cell carcinoma.
    Arasaratnam M; Gurney H
    Future Oncol; 2018 Jul; 14(17):1679-1689. PubMed ID: 29460635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in immunotherapy for kidney cancer.
    Ball MW; Allaf ME; Drake CG
    Discov Med; 2016 Apr; 21(116):305-13. PubMed ID: 27232516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line.
    Porta C; Giglione P; Paglino C
    Expert Opin Pharmacother; 2016; 17(5):643-55. PubMed ID: 26630127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.
    Venur VA; Joshi M; Nepple KG; Zakharia Y
    Drug Des Devel Ther; 2017; 11():1175-1182. PubMed ID: 28442891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
    O'Reilly A; Larkin J
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):251-262. PubMed ID: 28224821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
    Perego G; Barzaghi P; Vavassori I; Petrelli F
    Med Oncol; 2020 Aug; 37(9):81. PubMed ID: 32767163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).
    Atkins MB; Philips GK
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):243-54. PubMed ID: 27539246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions.
    Merza H; Bilusic M
    Curr Oncol Rep; 2017 Apr; 19(4):27. PubMed ID: 28303494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer.
    Rassy EE; Khoury Abboud RM; Ibrahim N; Assi T; Aoun F; Kattan J
    Immunotherapy; 2018 Sep; 10(12):1047-1052. PubMed ID: 30185138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
    Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
    Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.